Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1Endocrine 1

Conditions

Thyroid Carcinoma, Anaplastic 1

Interventions

Everolimus 32Octreotide 15Cisplatin 14pasireotide 13Sunitinib 13Temozolomide 11pembrolizumab 10Etoposide 10Doxorubicin 10lanreotide 9Magnetic Resonance Spectroscopy 9Bevacizumab 9lutetium Lu 177 dotatate 8gallium Ga 68 dotatate 8Sorafenib 8Paclitaxel 83-Iodobenzylguanidine 8lenvatinib 7pazopanib 6Radiotherapy 6Positron Emission Tomography Computed Tomography 6Nivolumab 6surufatinib 5cabozantinib 5avelumab 5Thyrotropin Alfa 5Surgical Procedures, Operative 5Radiosurgery 5Mitotane 5Irinotecan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × crolibulin × Endocrine × Clear all
NCT01240590 2017-04-10

A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
27 enrolled 15 charts
EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡